Abstract :

This case report examines an infant presenting with Epidermolysis Bullosa (EB) and severe anemia, highlighting the complexities of managing this condition. Despite receiving comprehensive care, EB significantly impacts patients’ quality of life due to chronic pain and psychosocial challenges. Effective management requires a multidisciplinary approach, with emphasis on wound care, pain management, and nutritional support. Targeted therapies, such as gene editing and protein replacement, offer promising avenues for improving outcomes in EB patients, emphasizing the importance of understanding underlying genetic mutations. Collaboration among healthcare professionals, researchers, and advocacy groups is essential for advancing EB management and enhancing patient care. This case underscores the urgent need for continued research efforts to address the unique challenges posed by EB and provide better support for affected individuals.

---

Keywords :

and patient, chronic pain, collaborative research, Epidermolysis Bullosa, gene editing, genetic mutations, multidisciplinary care, nutritional support, pain management, protein replacement, psychosocial challenges, Quality of life., severe anemia, wound care

---

References :

1. Gopidalai, K., Akum Arthi, J., & Devi, U. (Year). Epidermolysis bullosa with severe anaemia in an infant. Journal Name, Volume (Issue), Page range. DOI: 5281/zenodo.1023219
2. Hintner H, Stingl G, Schuler G, et al. Immunofluorescence mapping of antigenic determinants with the dermal-epidermal junction in the mechanobullous disease. J Invest Dermatol. 1981;76(2):113–118.
3. Fassihj H, McGrath JA. Prenatal diagnosis of epidermolysis bullosa. Dermatol Clin. 2010;28(2):231–237.
4. Hübner, F.; Recke, A.; Zillikens, D.; Linder, R.; Schmidt, E. Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in J. Investig. Dermatol. 2016, 136, 2495–2498.
5. Iwata, ; Vorobyev, A.; Koga, H.; Recke, A.; Zillikens, D.; Prost-Squarcioni, C.; Ishii, N.; Hashimoto, T.; Ludwig, R.J. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J. Rare Dis. 2018, 13, 153.
6. Salam, A.; Proudfoot, L.E.; McGrath, J.A. Inherited blistering skin diseases: Underlying molecular mechanisms and emerging therapies. Med. 2014, 46, 49–61.
7. Fine, D. (2010). “Inherited epidermolysis bullosa.” Orphanet Journal of Rare Diseases.
8. Pfendner, , & Bruckner, A. (2008). “Epidermolysis bullosa simplex.” GeneReviews.
9. Uitto, J., & Bruckner-Tuderman, L. (2010). “Dystrophic epidermolysis bullosa: pathogenesis and clinical features.” Dermatologic Clinics.
10. Has, (2011). “Junctional epidermolysis bullosa.” Dermatologic Clinics.
11. Pfendner, , & Bruckner, A. (2008). “Epidermolysis bullosa simplex.” GeneReviews.
12. Uitto, , & Bruckner-Tuderman, L. (2010).  “Dystrophic  epidermolysis      bullosa: pathogenesis and clinical features.” Dermatologic Clinics.
13. Woodley, T. et al. (2017). “Gene therapy for recessive dystrophic epidermolysis bullosa.” Science Translational Medicine.
14. Remington, et al. (2009). “Recombinant human type VII collagen for dystrophic epidermolysis bullosa.” Journal of Investigative Dermatology.
15. Mellerio, E. (2010). “Immunomodulatory agents in epidermolysis bullosa.” Dermatologic Clinics.